Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jane Pitt is active.

Publication


Featured researches published by Jane Pitt.


Journal of Acquired Immune Deficiency Syndromes | 2002

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Ellen R. Cooper; Manhattan Charurat; Lynne Mofenson; I. Celine Hanson; Jane Pitt; Clemente Diaz; Karen Hayani; Edward Handelsman; Vincent Smeriglio; Rodney Hoff; William Blattner

Context: The Women and Infants Transmission Study is a prospective natural history study that has been enrolling HIV‐1‐infected pregnant women and their infants since 1989. Objective: Toevaluate the impact of different antiretroviral regimens on perinatal HIV‐1 transmission at the population level. Design: Prospective cohort study. Plasma HIV‐1 RNA levels were serially measured in 1542 HIV‐1‐infected women with singleton live births between January 1990 and June 2000. Main Outcome Measure: HIV‐1 status of the infant. Results: HIV‐1 transmission was 20.0% (95% confidence interval [CI], 16.1%‐ 23.9%) for 396 women who not receiving prenatal antiretroviral therapy; 10.4% (95% CI, 8.2%‐12.6%) for 710 receiving zidovudine monotherapy; 3.8% (95% CI, 1.1%‐ 6.5%) for 186 receiving dual antiretroviral therapy with no or one highly active drug (Multi‐ART); and 1.2% (95% CI, 0‐2.5%) for 250 receiving highly active antiretroviral therapy (HAART). Transmission also varied by maternal delivery HIV RNA level: 1.0% for <400; 5.3% for 400 to 3499; 9.3% for 3500 to 9999; 14.7% for 10,000 to 29,999; and 23.4% for >30,000 copies/mL (p = .0001 for trend). The odds of transmission increased 2.4‐fold (95% CI, 1.7‐3.5) for every log10 increase in delivery viral load. In multivariate analyses adjusting for maternal viral load, duration of therapy, and other factors, the odds ratio for transmission for women receiving Multi‐ART and HAART compared with those receiving ZDV monotherapy was 0.30 (95% CI, 0.09‐1.02) and 0.27 (95% CI, 0.08‐0.94), respectively. Conclusion: Levels of HIV‐1 RNA at delivery and prenatal antiretroviral therapy were independently associated with transmission. The protective effect of therapy increased with the complexity and duration of the regimen. HAART was associated with the lowest rates of transmission.


The New England Journal of Medicine | 1999

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission

Patricia Garcia; Leslie A. Kalish; Jane Pitt; Howard Minkoff; Thomas C. Quinn; Sandra K. Burchett; Janet Kornegay; Brooks Jackson; John Moye; Celine Hanson; Carmen D. Zorrilla; Judy F. Lew

BACKGROUND The importance of plasma levels of human immunodeficiency virus type 1 (HIV-1) RNA in pregnant women in relation to the other factors known to influence the risk of transmission of infection to their infants is incompletely defined. We studied the relation of maternal plasma HIV-1 RNA levels to the risk of perinatal transmission and the timing of transmission. METHODS We measured plasma HIV-1 RNA serially in 552 women with HIV-1 infection who had singleton pregnancies. The status of infection in their infants was assessed by culture of blood and further classified as early (if a culture of blood obtained within the first two days of life was positive) or late (if a culture of blood obtained in the first seven days of life was negative but subsequent cultures were positive). The rates of transmission at various levels of maternal plasma HIV-1 RNA were analyzed by tests for trend, with adjustment for covariates by stratification and logistic regression. RESULTS Increasing geometric mean levels of plasma HIV-1 RNA were associated with increasing rates of transmission: the rate was 0 percent among women with less than 1000 copies per milliliter (0 of 57), 16.6 percent among women with 1000 to 10,000 copies per milliliter (32 of 193), 21.3 percent among women with 10,001 to 50,000 copies per milliliter (39 of 183), 30.9 percent among women with 50,001 to 100,000 copies per milliliter (17 of 55), and 40.6 percent among women with more than 100,000 copies per milliliter (26 of 64) (P<0.001). The treatment status of one woman was unknown. The highest rate of transmission was among women whose plasma HIV-1 RNA levels exceeded 100,000 copies per milliliter and who had not received zidovudine (19 of 30 women, 63.3 percent). Neither higher HIV-1 RNA levels early in pregnancy nor higher levels late in pregnancy were associated with the timing of infection in the infants. CONCLUSIONS In pregnant women with HIV-1 infection the level of plasma HIV-1 RNA predicts the risk but not the timing of transmission of HIV-1 to their infants.


Journal of Pediatric Surgery | 1974

An experimental study of acute neonatal enterocolitis—the importance of breast milk☆

Barbara Barlow; Thomas V. Santulli; William C. Heird; Jane Pitt; William A. Blanc; John N. Schullinger

Abstract Formula feeding in conjunction with hypoxia produces enterocolitis in newborn rats. Breast feeding under the same circumstances is completely protective. Enteric overgrowth of potentially pathogenic bacteria in only the formula-fed rats indicates that the gut flora plays an important role in the pathogenesis of enterocolitis. Breast milk through induction of passive enteric immunity and control of intestinal flora protects the rat and may protect at-risk premature infants from acute enterocolitis.


The New England Journal of Medicine | 1999

Cytomegalovirus Infection and HIV-1 Disease Progression in Infants Born to HIV-1–Infected Women

Andrea Kovacs; Mark Schluchter; Kirk A. Easley; Gail J. Demmler; William T. Shearer; Philip La Russa; Jane Pitt; Ellen R. Cooper; Johanna Goldfarb; David S. Hodes; Meyer Kattan; Kenneth McIntosh

Background and Methods Cytomegalovirus (CMV) has been implicated as a cofactor in the progression of human immunodeficiency virus type 1 (HIV-1) disease. We assessed 440 infants (75 of whom were HIV-1–infected and 365 of whom were not) whose CMV status was known, who were born to HIV-1–infected women, and who were followed prospectively. HIV-1 disease progression was defined as the presence of class C symptoms (according to the criteria of the Centers for Disease Control and Prevention [CDC]) or CD4 counts of less than 750 cells per cubic millimeter by 1 year of age and less than 500 cells per cubic millimeter by 18 months of age.


Journal of Acquired Immune Deficiency Syndromes | 2005

Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy

Ruth Tuomala; D. Heather Watts; Daner Li; Mark Vajaranant; Jane Pitt; Hunter Hammill; Sheldon Landesman; Carmen D. Zorrilla; Bruce Thompson

Data from 2543 HIV-infected women were analyzed to correlate antiretroviral therapy (ART) used during pregnancy with maternal and pregnancy outcomes. ART was analyzed according to class of agents used and according to monotherapy versus combination ART containing neither protease inhibitors (PIs) nor nonnucleoside reverse transcriptase inhibitors versus highly active ART. Timing of ART was classified according to early (recorded at or before 25-week gestation study visit) and late (recorded at 32-week gestation or delivery visit) use. Maternal outcomes assessed included hematologic, gastrointestinal, neurologic, renal, and dermatologic complications; gestational diabetes; lactic acidosis; and death. Adverse pregnancy outcomes assessed included hypertensive complications; pre-term labor or rupture of membranes; preterm delivery (PTD); low birth weight; and stillbirth. Logistic regression analyses controlling for multiple covariates revealed ART to be independently associated with few maternal complications: ART use was associated with anemia (odds ratio [OR] = 1.6, 95% confidence interval [CI]: 1.1-2.4), and late use of ART was associated with gestational diabetes (OR = 3.5, 95% CI: 1.2-10.1). Logistic regression analyses revealed an increase in PTD at <37 weeks for 10 women with late use of ART not containing zidovudine (ZDV; OR = 7.9, 95% CI: 1.4-44.6) and a decrease in adverse pregnancy outcomes as follows: late use of ART containing ZDV was associated with decreased risk for stillbirth and PTD at <37 weeks (OR = 0.06, 95% CI: 0.02-0.18; OR = 0.5, 95% CI: 0.3-0.8, respectively), and ART containing nucleoside reverse transcriptase inhibitors but not ZDV during early and late pregnancy was associated with decreased risk for PTD at <32 weeks (OR = 0.3, 95% CI: 0.2-0.7). Benefits of ART continue to outweigh observed risks.


Journal of Clinical Microbiology | 2003

Multicenter Evaluation of Use of Dried Blood and Plasma Spot Specimens in Quantitative Assays for Human Immunodeficiency Virus RNA: Measurement, Precision, and RNA Stability

Don Brambilla; Cheryl Jennings; Grace Aldrovandi; James W. Bremer; Anne Marie Comeau; Sharon A. Cassol; Ruth Dickover; J. Brooks Jackson; Jane Pitt; John L. Sullivan; Ann Butcher; Lynell Grosso; Patricia Reichelderfer; Susan A. Fiscus

ABSTRACT Eleven laboratories evaluated the use of dried blood and plasma spots for quantitation of human immunodeficiency virus (HIV) RNA by two commercially available RNA assays, the Roche Amplicor HIV-1 Monitor and the bioMerieux NucliSens HIV-1 QT assays. The recovery of HIV RNA was linear over a dynamic range extending from 4,000 to 500,000 HIV type 1 RNA copies/ml. The Monitor assay appeared to have a broader dynamic range and seemed more sensitive at lower concentrations. However, the NucliSens assay gave more consistent results and could be performed without modification of the kit. HIV RNA was stable in dried whole blood or plasma stored at room temperature or at −70°C for up to 1 year. Dried blood and dried plasma spots can be used as an easy and inexpensive means for the collection and storage of specimens under field conditions for the diagnosis of HIV infection and the monitoring of antiretroviral therapy.


The Journal of Pediatrics | 1996

Natural history of somatic growth in infants born to women infected by human immunodeficiency virus

Jack Moye; Kenneth Rich; Leslie A. Kalish; Amy R. Sheon; Clemente Diaz; Ellen R. Cooper; Jane Pitt; Edward Handelsman

OBJECTIVE To evaluate the nature and magnitude of the effect of congenitally or perinatally acquired human immunodeficiency virus (HIV) infection on somatic growth from birth through 18 months of age. STUDY DESIGN Anthropometry was performed serially in 282 term infants born to HIV-infected women in a multicenter prospective natural history cohort study. Repeated measures analysis was used to compare z-score anthropometric indexes of weight-for-age, length-for-age, weight-for-length, and head circumference-for-age between infected and uninfected infants, with adjustment for covariates including infant gender; maternal education; prenatal alcohol, tobacco, and/or illicit drug exposure; and mean prenatal CD4+ T-lymphocyte count. A separate repeated measures model was used to assess the effect of infant zidovudine treatment on growth. RESULTS Infants infected with HIV were an estimated average 0.28 kg lighter and 1.64 cm shorter than uninfected infants at birth, were 0.71 kg lighter and 2.25 cm shorter by 18 months of age, and had a sustained estimated average decrement of 0.70 to 0.75 cm in head circumference. Patterns of growth were similar in male and female infants. Infected infants had a progressive decrement in body mass index from birth through 6 months of age. Infection with HIV was associated with significant decrements across all standardized growth outcome measures after adjustment for covariates. Mean z scores were lower for weight by 0.612 (p < 0.001), for length by 0.735 (p < 0.001), for weight-for-length by 0.255 (p = 0.02), and for head circumference by 0.563 (p < 0.001) SD units compared with uninfected infants. Zidovudine treatment was not associated with improved growth. CONCLUSION The effect of congenitally or perinatally acquired HIV infection on infant growth is one of early and progressive decrements in attained linear growth and growth in mass, early and sustained decrements in head growth, and marked early decrements in body mass index.


Pediatric Research | 1977

Protection against Experimental Necrotizing Enterocolitis by Maternal Milk. I. Role of Milk Leukocytes

Jane Pitt; Barbara Barlow; William C. Heird

Summary: A ral model of necrotizing enterocolitis of the neonate in which maternal milk had been protective was studied to determine what components of the milk afforded protection and by what mechanism. Frozen and thawed rat milk was not protective, but formula supplemented with rat milk cells was. It was concluded that the cells provided protection. The cells, which are principally mononuclear phagocytes, can phagocytize and kill the Klebsiella pneumoniae strain used in the animal model. Animals with necrotizing enterolitis had peritonitis and bacteremia caused by this bacillus.Speculation: Milk mononuclear phagocytes may protect the neonatal rat from enterocolitis by their antibacterial and wound-healing activities or by their ability to enhance the neonatal immune response. The etiologic role of bacteria in this disease, not proven in these experiments, must be determined by experiments in germfree rats.


The New England Journal of Medicine | 1982

Deficiency of a Granulocyte-Membrane Glycoprotein (gp150) in a Boy with Recurrent Bacterial Infections

M. Amin Arnaout; Jane Pitt; Harvey J. Cohen; Julian Melamed; Fred S. Rosen; Harvey R. Colten

Abstract Investigation of the basis for increased susceptibility to infection with pyogenic organisms in an eight-year-old boy revealed a defect in receptor coupled polymorphonuclear-leukocyte func...


AIDS | 2000

HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study.

Seth L. Welles; Jane Pitt; Robert C. Colgrove; Kenneth McIntosh; Pei Hua Chung; Amy E. Colson; Shahin Lockman; Mary Glenn Fowler; Celine Hanson; Sheldon Landesman; John Moye; Kenneth Rich; Carmen D. Zorrilla; Anthony J. Japour

ObjectivesAlthough the treatment of pregnant women and their infants with zidovudine (ZDV) has been remarkably effective in preventing the perinatal transmission of human HIV-1, many potentially preventable infections still occur. To examine whether the risk of perinatal infection is increased among women who carry ZDV-resistant HIV-1, the role of genotypic ZDV resistance in perinatal transmission was evaluated. MethodsThe reverse transcriptase (RT) region of clinical isolates from culture supernatants of 142 HIV-1-infected women enrolled in the Women and Infants Transmission Study (WITS), who had been treated with ZDV during pregnancy was sequenced. Results from genotypic sequencing were linked to demographic, laboratory, and obstetrical databases, and the magnitude of association of having consensus drug-resistant HIV-1 RT mutations with transmission was estimated. ResultsTwenty-five per cent (34/142) of maternal isolates had at least one ZDV-associated resistance mutation. A lower CD4 cell percentage and count (P  = 0.0001) and higher plasma HIV-1 RNA (P  = 0.006) were associated with having any ZDV resistance mutation at delivery. Having any RT resistance mutation [odds ratio (OR): 5.16; 95% confidence interval (CI): 1.40, 18.97; P  = 0 0.01], duration of ruptured membranes [OR: 1.13 (1.02, 1.26) per 4 h duration; P  = 0.02], and total lymphocyte count [OR: 1.06 (1.01, 1.10) per 50 cells higher level; P  = 0.009] were independently associated with transmission in multivariate analysis. ConclusionMaternal ZDV resistant virus was predictive of transmission, independent of viral load, in these mothers with moderately advanced HIV-1 disease, many of whom had been treated with ZDV before pregnancy.

Collaboration


Dive into the Jane Pitt's collaboration.

Top Co-Authors

Avatar

Kenneth McIntosh

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Kenneth Rich

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar

Clemente Diaz

University of Puerto Rico

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Judy F. Lew

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Lynne M. Mofenson

Elizabeth Glaser Pediatric AIDS Foundation

View shared research outputs
Top Co-Authors

Avatar

Hermann Mendez

State University of New York System

View shared research outputs
Top Co-Authors

Avatar

John Moye

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Sheldon Landesman

SUNY Downstate Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge